Search results for "Colore"

showing 10 items of 1250 documents

Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.

2019

Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. The prognostic role of the number of retrieved and examined nodes, nodal ratio, and log odds of positive lymph nodes (LODDS) was analyzed and compared by receiver operating characteristic curves, Pearson t…

AdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerDisease-free survivalmedicine.medical_treatmentLODDSLocally advancedAdenocarcinomaDisease-Free SurvivalLog odds of positive lymph nodeRectal AdenocarcinomaMedicineHumansRectal cancerLog odds of positive lymph nodesNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overReceiver operating characteristicddc:617business.industryRectal NeoplasmsHazard ratioGeneral MedicineNodal ratioChemoradiotherapyMiddle Agedmedicine.diseasePrognosisConfidence intervalNeoadjuvant TherapyOncologydisease-free survival; lodds; log odds of positive lymph nodes; neoadjuvant therapy; nodal ratio; rectal cancer; adenocarcinoma; adult; aged; aged 80 and over; disease-free survival; female; humans; lymph nodes; male; middle aged; neoplasm recurrence Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Chemoradiotherapy; Neoadjuvant TherapyNeoadjuvant therapyFemaleRadiologyLymph NodesNeoplasm Recurrence LocalbusinessAnticancer research
researchProduct

Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.

1990

Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated with oral tegafur (TG) 1,000 mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable patients seven patients had a partial response (PR. 17%) with a median duration of 20.5 weeks, three had a minimal response (7%) with a median duration of 23.7 weeks, nine showed a stabilisation which lasted a median of 31.3 weeks, and 23 progressed (55%). No response was obtained in patients affected by carcinoma of the pancreas and the hepatobiliary system. All PRs were achieved in patients with metastatic disease to the liver. No response was seen in patients with bone, lung or noda…

AdultMaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentPhases of clinical researchAdministration OralTegafurGastroenterologyStomach NeoplasmsInternal medicinemedicineCarcinomaHumansAgedTegafurChemotherapyGastrointestinal tractbusiness.industryStomachMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureOncologyVomitingDrug EvaluationFemalemedicine.symptombusinessColorectal Neoplasmsmedicine.drugResearch ArticleBritish Journal of Cancer
researchProduct

Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.

2010

Purpose To assess response of locally advanced rectal carcinoma to chemoradiation with regard to mucinous status and local tumor invasion found at pretherapeutic magnetic resonance imaging (MRI). Methods and Materials A total of 88 patients were included in this prospective study of patients with advanced mrT3 and mrT4 carcinomas. Carcinomas were categorized by MRI as mucinous (mucin proportion >50% within the tumor volume), and as nonmucinous. Patients received neoadjuvant chemoradiation consisting of 50.4 Gy (1.8 Gy/fraction) and 5-fluorouracil on Days 1 to 5 and Days 29 to 33. Therapy response was assessed by comparing pretherapeutic MRI with histopathology of surgical specimens (minimum…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyAntimetabolites AntineoplasticNeoplasm ResidualColorectal cancerRectumDrug Administration SchedulemedicineMucinous carcinomaHumansRadiology Nuclear Medicine and imagingNeoplasm InvasivenessProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overRadiationmedicine.diagnostic_testbusiness.industryRectal NeoplasmsCarcinomaDose fractionationMagnetic resonance imagingChemoradiotherapyMiddle Agedmedicine.diseaseAdenocarcinoma MucinousMagnetic Resonance ImagingNeoadjuvant TherapyTumor Burdenmedicine.anatomical_structureTreatment OutcomeOncologyAdenocarcinomaHistopathologyFemaleRadiologyDose Fractionation RadiationFluorouracilbusinessInternational journal of radiation oncology, biology, physics
researchProduct

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study

2005

The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival a…

AdultMaleCancer Researchmedicine.medical_specialtyRandomization5-fluorouracil modulation; adjuvant chemotherapy; colorectal cancermedicine.drug_classColorectal cancerLeucovorincolorectal cancerAntimetaboliteGastroenterologyDisease-Free SurvivalFolinic acidRECTAL CANCER5-fluorouracil modulationCOLONInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAgedbusiness.industryHazard ratioMiddle Agedmedicine.diseaseSurgeryadjuvant chemotherapyTreatment OutcomeLevamisoleOncologyChemotherapy AdjuvantFluorouracilVomitingFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Del…

2005

Purpose We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer. Patients and Methods A total of 360 chemotherapy-naive patients were randomly assigned to receive, every 2 weeks, either arm A (FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2 [LV5FU2]) or arm B (FOLFOX4: oxaliplatin 85 mg/m2 on day 1 with LV5FU2 regi…

AdultMaleCancer Researchmedicine.medical_specialtyRandomizationOrganoplatinum CompoundsColorectal cancerfolinic acidatropineplatinum complexLeucovorinGastroenterologylaw.inventionRandomized controlled trialFolfox protocollawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intravenousirinotecanantineoplastic agentAgedbusiness.industryoxaliplatinMiddle Agedmedicine.diseaseSurvival AnalysisOxaliplatinSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracildrug derivativeDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilIFL protocolColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Tobacco smoking and alcohol consumption as risk factors for thymoma - A European case-control study

2019

PURPOSE: Hardly anything is known about the aetiology of thymoma. This paper presents data regarding tobacco smoking and alcohol consumption in relation to thymoma from the first case-control study performed on this rare tumour.METHODS: A European multi-centre case-control study including incident cases aged 35-69 years with thymoma between 1995 and 1997, was conducted in seven countries. A set of controls, used in seven parallel case-control studies by the same research group was used, including population-based controls from five countries and hospital controls with colon cancer from two countries. Altogether 103 cases, accepted by a reference pathologist, 712 colon cancer controls, and 2…

AdultMaleCancer Researchmedicine.medical_specialtyThymomaAlcohol DrinkingThymomaEpidemiologyColorectal cancerThymus cancerPopulationMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineeducationAgedAlcohol; Case-control study; Risk factors; Thymoma; Thymus cancer; Tobacco smokingeducation.field_of_studybusiness.industryCase-control studyCase-control studyMiddle Agedmedicine.diseaseTobacco smokingIncreased riskOncologyRisk factorsCase-Control Studies030220 oncology & carcinogenesisEtiologyFemalebusinessAlcoholAlcohol consumption
researchProduct

Identification of resources and skills developed by partners of patients with advanced colon cancer: a qualitative study

2018

National audience; Les aidants familiaux jouent un rôle central auprès des patients présentant un cancer de stade avancé. Parmi les proches susceptibles d’apporter une aide aux personnes malades, les conjoints, en raison des liens qui les unissent et parce qu’ils partagent leur vie quotidienne, sont sans doute les plus confrontés à la maladie. Ils sont également majoritairement désignés comme étant l’aidant principal. L’irruption de la maladie et le besoin d’accompagnement qu’elle nécessite, viennent bouleverser en profondeur les différents équilibres structurant leur quotidien et leur organisation. Ils viennent aussi questionner la nature des relations qu’ils entretiennent, dans une divers…

AdultMaleColorectal cancerHealth PersonnelEmotions[SHS.PSY]Humanities and Social Sciences/Psychology[SDV.CAN]Life Sciences [q-bio]/Cancer[SHS.PSY] Humanities and Social Sciences/Psychology03 medical and health sciences0302 clinical medicineNursingMedicineHumans030212 general & internal medicineQualitative ResearchCancer[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyFamily caregiversbusiness.industryNursing researchSkillsFocus GroupsMiddle Agedmedicine.diseaseFocus groupAdvanced cancer3. Good healthIdentification (information)Cross-Sectional StudiesOncologyCaregivers[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie030220 oncology & carcinogenesisColonic NeoplasmsHealth Resources[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFemaleClinical CompetenceFranceDependantbusinessQualitative[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyQualitative research
researchProduct

High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression

2013

Tryptase(+) mast cells (MCs), abundant in the invasive front of tumours, contribute to tissue remodelling. Indeed, protease-activated receptor- 2 (PAR-2) activation by MC-tryptase is considered an oncogenic event in colorectal cancer (CRC). Recently, we have suggested NHERF1 as a potential new marker in CRC. In this study, we aimed to determine the distribution of tryptase(+) MCs and PAR-2 and to examine the relationship between PAR-2 and NHERF1, investigating their reputed usefulness as tumour markers. We studied a cohort of 115 CRC specimens including primary cancer (C) and adjacent normal mucosa (NM) by immunohistochemical double staining, analyzing the protein expression of MC-tryptase,…

AdultMaleCytoplasmPathologymedicine.medical_specialtySodium-Hydrogen ExchangersColorectal cancerLymphovascular invasionSettore MED/06 - Oncologia MedicainvasivenesstryptasePAR-2Cell CountTryptaseModels BiologicalImmunophenotypingNHERF1Intestinal mucosamedicineHumansReceptor PAR-2Mast CellsIntestinal Mucosaprognostic factorProtease-activated receptor 2AgedAged 80 and overbiologyColorectal cancer PAR-2 mast cell tryptase NHERF1 prognostic factor invasiveness aggressivenessOriginal ArticlesCell BiologyaggressivenessMiddle AgedPhosphoproteinsPrognosismedicine.diseaseMast cellColorectal cancermedicine.anatomical_structurebiology.proteinMolecular MedicineImmunohistochemistryFemaleTryptasesmast cellColorectal Neoplasms
researchProduct

Changes in pattern induced flicker colors are mediated by the blue-yellow opponent process.

1992

The colors of Benham's Top [pattern induced flicker colors (PIFCs)] were matched with color stimuli provided by a computer aided color mixer. Subjects viewed a series of specifically modified black and white disks and matched the resulting subjective color with a comparison field containing the color generated by additive mixing. Different phase relations between the apparently colored ring and the surround were tested. The color loci of all PIFCs were found to lie on a plane in receptor three-space which is given by the axis of the shortwave receptor excitation and a vector given by combining the middle and long wave receptor excitation directions in a fixed ratio of nearly 1:1. From the o…

AdultMaleLightColor visionPhase (waves)OpticsmedicinePsychophysicsHumansColor perception testPhotoreceptor CellsPhysicsColor Perception Testsmedicine.diagnostic_testbusiness.industryPlane (geometry)FlickerOpponent processSensory SystemsOphthalmologyColoredPattern Recognition VisualFemalebusinessColor PerceptionPhotic StimulationVision research
researchProduct

Metabolite profiling of fecal water extracts from human colorectal cancer.

2009

Colorectal cancer is the second leading cause of cancer death in developed countries. There is a need for better preventive strategies to improve the outcome of this disease. The increasing availability of high-throughput methodologies opens up new possibilities for screening new markers. The application of NMR metabolic profiling to fecal water extracts has interesting potential as a diagnostic tool for detecting colorectal cancer. We obtained NMR metabolic profiles of fecal water extracts from patients with colorectal cancer and healthy individuals, to characterize possible differences between them and to identify potential diagnostic markers. Our results show that metabolic profiling of …

AdultMaleMagnetic Resonance SpectroscopyColorectal cancerButyrateDiseaseBiologyComplex MixturesBioinformaticsFecesMetabolomicsmedicineHumansMetabolomicsRadiology Nuclear Medicine and imagingSpectroscopyAgedPrincipal Component AnalysisCase-control studyWaterMiddle Agedmedicine.diseaseMucusFecal waterMetabolite profilingCase-Control StudiesCancer researchMolecular MedicineFemaleColorectal NeoplasmsNMR in biomedicine
researchProduct